texas oncology more breakthroughs. more victories



Carlos Becerra, M.D.


Universidad del Valle; Fellowship: UT Southwestern Medical Center Hematology and Medical Oncology; Residency: Saint Francis Hospital Chief Resident Internal Medicine 1993-1994, PG-2 and PG-3 1992-1994, PG-1 Internal Medicine 1991-1992.

Why a patient should choose treatment at your practice?

We provide comprehensive care to our patients using a multi-disciplinary approach. We also offer unique clinical trials and believe in the importance of support systems. 

What is your personal philosophy around patient care?

Personal, holistic approach.


Show all Publications
  • Phase 1 Study of MRX34, a Liposomal miR-34a Mimic, in Patients With Advanced Solid Tumours

    British Journal of Cancer, 2020

  • Phase I Dose-Escalation Trial of the Oral AKT Inhibitor Uprosertib in Combination With the Oral MEK1/MEK2 Inhibitor Trametinib in Patients With Solid Tumors

    Cancer Chemotherapy and Pharmacology, 2020

  • A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of Taselisib (GDC-0032) in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced, or Metastatic Breast Cancer

    Breast Cancer Research and  Treatment, 2019

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    The New England Journal of Medicine, 2019

  • Open-Label Study To Evaluate Trifluridine/Tipiracil Safety, Tolerability and Pharmacokinetics in Patients With Advanced Solid Tumours and Hepatic Impairment

    British Journal of Clinical Pharmacology, 2019

  • Targeting LIF-Mediated Paracrine Interaction for Pancreatic Cancer Therapy and Monitoring

    Nature, 2019

  • Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

    Clinical Cancer Research, 2018

  • Locally Advanced Carcinosarcoma of the Pancreas

    Proceedings (Baylor University. Medical Center), 2018

  • Pembrolizumab Versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro-oesophageal Junction Cancer (KEYNOTE-061): a Randomised, Open-label, Controlled, Phase 3 Trial

    The Lancet, 2018

  • Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

    Clinical Cancer Research, 2018

  • Extended Dosing With CC-486 (Oral Azacitidine) in Patients With Myeloid Malignancies

    American Journal of Hematology, 2018

  • Phase 1/1b Dose Escalation and Expansion Study of BEZ235, a Dual PI3K/mTOR Inhibitor, in Patients With Advanced Solid Tumors Including Patients With Advanced Breast Cancer

    Cancer Chemotherapy and Pharmacology, 2018

  • Genome-Wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

    Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2018

  • A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil

    Journal of Clinical Pharmacology, 2017

  • Effect of Everolimus on the Pharmacokinetics of Octreotide Long-Acting Repeatable in Patients With Advanced Neuroendocrine Tumors: An Analysis of the Randomized Phase III RADIANT-2 Trial

    Clinical Pharmacology and Therapeutics, 2017

  • Patient-reported Symptoms of Tenosynovial Giant Cell Tumors

    Clinical Therapeutics, 2016

  • A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in patients with Advanced Cancer

    Clinical Cancer Research, 2016

  • A Phase I Clinical Trial of ASG-5ME, a Novel Drug-antibody Conjugate Targeting SLC44A4, in Patients with Advanced Pancreatic and Gastric Cancers

    Investigational New Drugs, 2016

  • Randomized Phase 1 Crossover Study Assessing the Bioequivalence of Capsule and tTablet formulations of Dovitinib (TKI258) in Patients with Advanced Solid Tumors

    Cancer Chemotherapy and Pharmacology, 2016

  • Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

    Oncology, 2016

  • A Phase I Trial of Panobinostat (LBH589) in Patients with Metastatic Melanoma

    Cancer Medicine, 2016

  • An Innovative, Multi-arm, Complete Phase 1b Study of the Novel Anti-cancer Agent Tasisulam in Patients with Advanced Solid Tumors

    Investigational New Drugs, 2015

  • Phase I Study of the MEK Inhibitor Trametinib in Combination with the AKT Inhibitor Afuresertib in Patients with Solid Tumors and Multiple Myeloma

    Cancer Chemotherapy and Pharmacology, 2015

  • Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KHL Conjugate Vaccines for Follicular Lymphoma

    BioMed Research International, 2015

  • Figitumumab in Patients with Refractory Metastatic Colorectal Cancer Previously Treated with Standard Therapies: a Nonrandomized, Open-label, Phase II Trial

    Cancer Chemotherapy and Pharmacology, 2014

  • A Phase I Dose-escalation Study of MEDI-575, a PDGFRα Monoclonal Antibody, in Adults with Advanced Solid Tumors

    Cancer Chemotherapy and Pharmacology, 2014

  • Phase 2 Trial of Afatinib, an ErbB Family Blocker, in Solid Tumors Genetically Screened for Target Activation

    Cancer, 2013

  • A Phase II Study with Cetuximab and Radiation Therapy with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92

    Journal of Thoracic Oncology, 2013

  • Safety. Pharmacokinetic, Pharmacodynamic, and Efficacy Data for the Oral MEK Inhibitor Trametinib: a Phase I Dose-escalation Trial

    Lancet Oncology, 2012

  • Gemcitabine Plus Enzaustarin or Single-agent Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: Results of a Phase II, Randomized, Noncomparative Study

    Investigational New Drugs, 2011

  • Referral Patterns and Adjuvant Chemotherapy use in Patients With Stage II Colon Cancer

    Clinical Colorectal Cancer, 2011

  • Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

    Clinical Cancer Research, 2010

  • Phase I Dose Escalation Study with Irinotecan, Capecitabine, Epirubicin, and Granulocyte Colony-stimulating Factor Support for Patients with Solid Malignancies

    American Journal of Clinical Oncology, 2008

  • The Continuum of Care: a Paradigm for the Management of Metastatic Colorectal Cancer

    Oncologist, 2007

  • Adverse Effects of Bevacizumab and Their Management in Solid Tumors

    Supportive Cancer Therapy, 2006

  • Efficacy of Sequential Treatment of HCT116 Colon Cancer Monolayers and Aenografts with Docetaxel, Flavopiridol, and 5-fluorouracil

    Acta Pharmacologica Sinica, 2006

  • A Phase II Clinical and Pharmacokinetic Study of Intravenous Exatecan Mesylate (DX-8951f) in Patients with Untreated Metastasis Gastric Cancer

    Investigational New Drugs, 2005

  • Dissecting Role of Regulatory Factors in NF-kB Pathway with siRNA

    Acta Pharmacologica Sinica, 2005

  • Selective Identification of Secreted and Transmembrane Breast Cancer Markers using Escherichia Coli Ampicillin Secretion Trap

    Cancer Research, 2005

  • A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers

    American Journal of Clinical Oncology, 2005

  • IҝB Kinase α(IKKα) Regulates Sub-cellular Distribution and Turnover of Cyclin D1 by Phosphorylation

    Journal of Biological Chemistry, 2005

  • Enhanced Chemosensitivity to Irinotecan by RNA Interference Mediated Down-regulation of the NF-kB p65 Subunit

    Clinical Cancer Research, 2004

  • Irinotecan, Epirubicin, and Capecitabine in Metastatic Adenocarcinomas: Preliminary Results of a Phase I Study

    Oncology (Williston Park), 2004

  • Identification and Validation of Genes Involved in the Pathogenesis of Colorectal Cancer Using cDNA Microarrays and RNA Interference

    Clinical Cancer Research, 2003

  • Small Interfering RNAs Directed Against B-Catenin Inhibit the In-vitro and In-vivo Growth of Colon Cancer Cells

    Clinical Cancer Research, 2003

  • Increased Toxicity and Lack of Efficacy of Rofecoxib in Combination with Chemotherapy for Treatment of Metastatic Colorectal Cancer: A Phase II Study

    International Journal of Cancer, 2003

  • Phase II Study of Pemetrexed Disodium (Alimta(R)) Administered with Oral Folic Acid in Patients with Advanced Gastric Cancer

    Annals of Oncology, 2003

  • Reversible Renal Toxicity Resulting From high single Doses of the New Radiosensitizer Gadolinium Texaphyrin

    American Journal of Clinical Oncology, 2000

  • A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging

    Clinical Cancer Research, 1999

  • Palmitoyl-Protein Thioesterase Deficiency in a Novel Granular Variant of Late Infantile Neuronal Ceroid Lipofuscinosis

    Pediatric Neurology, 1998

  • Mutations in the Palmitoyl Protein Thioesterase Gene (PPT;CLN1) Causing Juvenile Neuronal Ceroid Lipofuscinosis with Granular Osmiophilic Deposits

    Human Molecular Genetics, 1998

  • Molecular Genetics of Palmitoyl Protein Thioesterase Deficiency in the U.S.

    Journal of Clinical Investigation, 1998

Accolades & Memberships

  • American Association for Cancer Research
  • American Society of Clinical Oncology
  • Colombian Medical Association